Head-to-head evidence
Rosuvastatin vs UIC201604
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Atherosclerotic Cardiovascular Disease
Shared mechanism: HMG-CoA reductase · full Atherosclerotic Cardiovascular Disease pipeline
Rosuvastatin
Marketed by AstraZeneca
NCT04964544 · Phase 3 · completed
This was a large but open-label, single-arm, uncontrolled study, so there was no randomization, blinding, or comparator arm. Its primary outcomes were descriptive self-selection measures and LDL-C change rather than a controlled clinical outcome, and no formal between-group primary endpoint comparison could be assessed.
Next expected readout: October 2026 · NCT06603363 (registry estimate)
UIC201604
Developed by Korea United Pharm
NCT07600385 · Phase 3 · completed
The study randomized 260 participants to UI022/UI023 or an active comparator and masked both participants and investigators. Its primary endpoint was change in the KPAQ summary score at week 24. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Rosuvastatin's landscape · UIC201604's landscape